Phase 2 Trial is Enrolling Participants to Assess the True Prevalence of Allergic Reactions to COVID-19 Vaccines
source: pixabay.com

Phase 2 Trial is Enrolling Participants to Assess the True Prevalence of Allergic Reactions to COVID-19 Vaccines

A new study, funded by the NIH and conducted by Vanderbilt University Medical Center (VUMC), is working to assess allergic reactions to COVID-19 vaccines. The trial will include individuals between…

Continue Reading Phase 2 Trial is Enrolling Participants to Assess the True Prevalence of Allergic Reactions to COVID-19 Vaccines
Atypical Form of Guillain-Barré Syndrome Found Following COVID-19 Vaccination
source: pixabay.com

Atypical Form of Guillain-Barré Syndrome Found Following COVID-19 Vaccination

Two new reports of Guillain-Barré syndrome (GBS) have been documented in response to the AstraZeneca COVID-19 vaccine. Previously, published papers have documented 4 cases in England and 7 cases in…

Continue Reading Atypical Form of Guillain-Barré Syndrome Found Following COVID-19 Vaccination

CureVac Joins the Race to Develop a Vaccine Against COVID-19 With Its Successful Phase 1 Trial

According to an article in Biospace, CureVac of Boston, MA, with headquarters in Tübingen, Germany, just announced interim results from its Phase 1 study evaluating CVnCoV, a vaccine candidate against…

Continue Reading CureVac Joins the Race to Develop a Vaccine Against COVID-19 With Its Successful Phase 1 Trial
Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease
Free-Photos / Pixabay

Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease

According to an article in The Asahi Shimbun, Japanese scientists have developed a new vaccine to mitigate neuronal degeneration caused by Alzheimer's disease. The vaccine, delivered nasally, had promising results…

Continue Reading Nasal Vaccine Prevents Neuronal Loss in Mice Models of Alzheimer’s Disease